The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Tumor Blood Testing Market Over The 2026–2030 Period?
The tumor blood testing market has experienced rapid expansion in its size over recent years. It is projected to grow from $5.98 billion in 2025 to $6.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.3%. This historical growth can be primarily attributed to the rise in cancer prevalence, limitations of tissue biopsy, advancements in genomic testing, oncology research funding, and a strong demand for non-invasive diagnostics.
The tumor blood testing market is anticipated to experience significant expansion in the coming years. This market is projected to reach $11.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.2%. Factors contributing to this growth during the forecast period include early cancer screening programs, AI-enabled genomic analysis, the rise of personalized medicine, the broadening scope of companion diagnostics, and increased adoption in clinical trials. Key trends observed in this period encompass the widespread adoption of liquid biopsy, advancements in multi-cancer early detection, enhanced minimal residual disease monitoring, specialized personalized oncology testing, and the development of high-sensitivity biomarker detection methods.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report
Which Important Drivers Are Guiding The Tumor Blood Testing Market Growth?
The rising incidence of cancer is anticipated to propel expansion within the tumor blood testing market over the next few years. Demographic shifts towards older populations, coupled with exposure to various risk factors like unhealthy eating habits, tobacco use, and environmental contaminants, are leading to a greater number of cancer cases, thereby boosting the need for early diagnostic tools. Tumor blood testing offers a less invasive way to identify cancer by detecting specific biomarkers in the bloodstream even before clinical symptoms manifest. This method facilitates prompt diagnosis, allows for earlier therapeutic interventions, enhances patient recovery prospects, and permits continuous tracking of disease advancement and treatment efficacy. For example, data from May 2024, provided by the National Cancer Institute, a US-based government agency, indicated that the United States had approximately 18.1 million cancer survivors as of January 2022, with forecasts suggesting this figure will climb to 26 million by 2040. Consequently, the expanding occurrence of cancer is a key factor stimulating the growth of the tumor blood testing market.
How Is The Tumor Blood Testing Market Broken Down By Segment Categories?
The tumor blood testing market covered in this report is segmented –
1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types
2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays
3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma
4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring
5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells
2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA
3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes
4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests
What Trends Are Influencing The Evolution Of The Tumor Blood Testing Market?
Leading companies in the tumor blood testing market are concentrating on developing innovative technologies, such as non-invasive liquid biopsy techniques, to enable earlier cancer detection, monitor treatment efficacy, and assess disease progression more effectively. These non-invasive liquid biopsy technologies are diagnostic tests that detect and analyze cancer-related biomarkers from bodily fluids, offering a safer and more convenient option than traditional tissue biopsies. For example, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, launched the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test for cancer monitoring. This assay analyzes cell-free DNA (cfDNA) fragments in the bloodstream to assess tumor burden and treatment response. This fragmentome-based liquid biopsy presents a non-invasive, cost-effective alternative to traditional methods, requiring minimal plasma and yielding results within two weeks.
Which Players Are Present In The Tumor Blood Testing Market Space?
Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.
Get The Full Tumor Blood Testing Market Report:
https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report
Which Region Leads The Tumor Blood Testing Market In Overall Market Size?
North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Tumor Blood Testing Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report
Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2026, By The Business Research Company
Hemato Oncology Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report
Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Blood Screening Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model